瑞波西利用于绝经后HR+/HER2-,luminal B型乳腺癌新辅助治疗:CORALLEEN研究  

Ribociclib for Postmenopausal Women With Hormone Receptor⁃Positive,HER2⁃Negative,Luminal B Breast Cancer:CORALLEEN Study

作　　者：胡泓 林颖怡 HU Hong;LIN Ying-yi(Department of Breast Surgery,The Second Clinical Medical College of Jinan University,The First Affiliated Hospital of Southern University of Science and Technology,Shenzhen People’s Hospital,Guangdong Shenzhen 518020,China;不详)

机构地区：[1]深圳市人民医院乳腺外科,暨南大学第二临床医学院,南方科技大学第一附属医院,广东深圳518020 [2]南方医科大学附属广东省人民医院(广东省医学科学院)乳腺肿瘤科,广州510080

出　　处：《循证医学》2023年第2期88-91,共4页The Journal of Evidence-Based Medicine

摘　　要：1文献来源Prat A,Saura C,Pascual T,et al.Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor⁃positive,HER2⁃negative,luminal B breast cancer(CORALLEEN):an open⁃label,multicentre,randomised,phase 2 trial[J].Lancet Oncol,2020,21(1):33-43.

关 键 词：瑞波西利 新辅助治疗 激素受体阳性 乳腺癌 

分 类 号：R737.9[医药卫生—肿瘤]